Anixa Biosciences is trading 9.84% up at $3.35 after reporting updated positive survival observations from its ongoing Phase 1 lira-cel ovarian-cancer CAR-T trial.
- Patients are surviving substantially beyond expected median survival, supporting optimism around the investigational therapy.
- Shares fell 2.56% during regular trading on September 3, 2026, making the after-hours rebound notable.